

DRAFT

ANTI-INFECTIVES-SYSTEMIC	
ANTIVIRALS	
Hepatitis C Agents	
Preferred	Non-Preferred
Copegus® Tablet Moderiba® Dosepack (branded generic for Ribasphere® Ribapak) Moderiba® Tablet (branded generic for Copegus®) Pegasys® Proclick / Syringe ribavirin capsule / tablet (generic for Copegus®, Rebetol®)	Pegasys® Vial Ribasphere® Ribapak Ribasphere® Capsule / Tablet (branded generic for Rebatrol)
Clinical criteria apply November 1, 2017- April 30, 2018	
STEP 1	
<u>All genotypes without cirrhosis</u> Mayvret™ (8 weeks of therapy)	Daklinza™ Tablet (for genotype 3) (must request Sovaldi® in addition to Daklinza® with a separate PA)
<u>All genotypes with compensated cirrhosis (Child Pugh-A)</u> Mayvret™ (12 weeks of therapy)	Epclusa® Tablet (for genotype 1,4,5 and 6) Olysio® Capsule Sovaldi® Tablet
	Technivie™ Dose Pack (for genotype 4)
STEP 2	
<u>All genotypes with decompensated cirrhosis (Child-Pugh B and C)</u> Epclusa® Tablet (for genotype 2 and 3) in combination with ribavirin	Viekira™ Pak Viekira™ XR Tablet Zepatier® Tablet
STEP 3	
<u>All genotypes previously treated with an HCV regimen containing an NS5A inhibitor or genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.</u> Vosevi™	
Technivie® Dose Pack (for genotype 4)	

Viekira® Pak Viekira® XR Tablet Zepatier® Tablet Harvoni® Tablet (for completion of therapy initiated prior to November 1, 2017)	
Clinical criteria apply 5/1/2018 and after	
STEP 1 All genotypes without cirrhosis Mayvret™ (8 weeks of therapy) All genotypes with compensated cirrhosis (Child Pugh-A) Mayvret™ (12 weeks of therapy)	Daklinza™ Tablet (for genotype 3) (must request Sovaldi® in addition to Daklinza® with a separate PA) Epclusa® Tablet (for genotype 1,4,5 and 6) Harvoni® Tablet Olysio® Capsule Sovaldi® Tablet
STEP 2 <u>All genotypes with decompensated cirrhosis</u> Epclusa® Tablet (for genotype 2 and 3) in combination with ribavirin	Technivie™ Dose Pack (for genotype 4) Viekira™ Pak
STEP 3 <u>All genotypes previously treated with an HCV regimen containing an NS5A inhibitor or genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.</u> Vosevi™	Viekira™ XR Tablet Zepatier® Tablet
Harvoni® Tablet Epclusa® Tablet (for genotype 2 and 3) Technivie® Dose Pack (for genotype 4) Viekira® Pak Viekira® XR Tablet Zepatier® Tablet	